Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

ver descrição completa

Detalhes bibliográficos
Principais autores: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Formato: Artigo
Idioma:English
Publicado em: Korean Association for the Study of Intestinal Diseases 2022-01-01
coleção:Intestinal Research
Assuntos:
Acesso em linha:http://irjournal.org/upload/pdf/ir-2020-00117.pdf